ATE500513T1 - Die proteinserum-amyloid p-komponente (sap, samp) als prognose- und diagnose-marker für die pränatale diagnose von trisomie 21 (down syndrom) - Google Patents

Die proteinserum-amyloid p-komponente (sap, samp) als prognose- und diagnose-marker für die pränatale diagnose von trisomie 21 (down syndrom)

Info

Publication number
ATE500513T1
ATE500513T1 AT08386023T AT08386023T ATE500513T1 AT E500513 T1 ATE500513 T1 AT E500513T1 AT 08386023 T AT08386023 T AT 08386023T AT 08386023 T AT08386023 T AT 08386023T AT E500513 T1 ATE500513 T1 AT E500513T1
Authority
AT
Austria
Prior art keywords
diagnosis
trisomy
down syndrome
samp
sap
Prior art date
Application number
AT08386023T
Other languages
English (en)
Inventor
George Tsangaris
Konstantinos Vougas
Aggeliki Kolialexi
Ariadni Mavrou-Kalpini
Aristidis Antsaklis
Original Assignee
Foundation Of Biomedical Res Of The Academy Of Athens
George Tsangaris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation Of Biomedical Res Of The Academy Of Athens, George Tsangaris filed Critical Foundation Of Biomedical Res Of The Academy Of Athens
Application granted granted Critical
Publication of ATE500513T1 publication Critical patent/ATE500513T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT08386023T 2007-10-26 2008-10-13 Die proteinserum-amyloid p-komponente (sap, samp) als prognose- und diagnose-marker für die pränatale diagnose von trisomie 21 (down syndrom) ATE500513T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20070100651A GR1006121B (el) 2007-10-26 2007-10-26 Η πρωτεϊνη serum amyloid p-component (sap,samp) ως προγνωστικος και διαγνωστικος δεικτης για τον προγεννητικο ελεγχο της τρισωμιας 21 (συνδρομο down)

Publications (1)

Publication Number Publication Date
ATE500513T1 true ATE500513T1 (de) 2011-03-15

Family

ID=40030173

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08386023T ATE500513T1 (de) 2007-10-26 2008-10-13 Die proteinserum-amyloid p-komponente (sap, samp) als prognose- und diagnose-marker für die pränatale diagnose von trisomie 21 (down syndrom)

Country Status (11)

Country Link
EP (1) EP2053407B1 (de)
AT (1) ATE500513T1 (de)
CY (1) CY1112415T1 (de)
DE (1) DE602008005228D1 (de)
DK (1) DK2053407T3 (de)
ES (1) ES2362051T3 (de)
GR (1) GR1006121B (de)
HR (1) HRP20110371T1 (de)
PL (1) PL2053407T3 (de)
PT (1) PT2053407E (de)
SI (1) SI2053407T1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104849471A (zh) * 2015-04-22 2015-08-19 戴勇 唐氏综合征图谱模型的构建方法
CN112924686B (zh) * 2019-12-05 2024-08-23 复旦大学 用于检测血清淀粉样蛋白a的免疫层析试纸条及其制备与检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
WO2005021793A1 (en) 2003-08-29 2005-03-10 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
JP5068543B2 (ja) 2004-02-16 2012-11-07 プロテオジス アクチェンゲゼルシャフト がんに関する診断マーカー

Also Published As

Publication number Publication date
CY1112415T1 (el) 2015-12-09
SI2053407T1 (sl) 2011-06-30
EP2053407B1 (de) 2011-03-02
DE602008005228D1 (de) 2011-04-14
ES2362051T3 (es) 2011-06-27
GR1006121B (el) 2008-10-24
EP2053407A1 (de) 2009-04-29
DK2053407T3 (da) 2011-06-20
HRP20110371T1 (hr) 2011-06-30
PL2053407T3 (pl) 2011-07-29
PT2053407E (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
Nankervis et al. Testing for gestational diabetes mellitus in Australia
WO2007147076A3 (en) Methods for the diagnosis of fetal abnormalities
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
TW200700558A (en) A method for the detection of chromosomal aneuploidies
EP4235181A3 (de) Biomarkerdetektionsverfahren und test für neurologischen zustand
EP2612927A3 (de) Marker zur pränatalen Diagnose und Überwachung
EP1689884A4 (de) Verfahren zur pränatalen diagnose chromosomaler abnormalitäten
WO2010132447A3 (en) Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
EP2727935A3 (de) Mit Frühstadium und anderen Stadien von Brustkrebs assoziierte Serummarker
EP2081029A3 (de) Biomarker zur Diagnose diabetischer Retinopathie
EP4273548A3 (de) Serologischer test für stumme hirnischämie
CA2645302C (en) Diagnosis and prognosis of dipeptidyl peptidase-associated disease states
WO2007106838A3 (en) A non-invasive method for diagnosing fetal cells and cancer cells
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE500513T1 (de) Die proteinserum-amyloid p-komponente (sap, samp) als prognose- und diagnose-marker für die pränatale diagnose von trisomie 21 (down syndrom)
WO2014117680A3 (zh) 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆
WO2007140971A3 (en) Cell adhesion proteins as biomarker for alzheimer's disease
BR112014007947A2 (pt) método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
BR112013030646A2 (pt) uso diagnóstico de pró-somatostatina
DE602006013453D1 (de) Verfahren zur anreicherung fötaler zellen
WO2008035204A3 (en) Prediction and prophylactic treatment of type 1 diabetes
Korolenko et al. Cystatins: cysteine proteases regulation and disturbances in tumors and inflammation
WO2016010401A8 (ko) 산모의 혈청 dna를 이용한 태아의 단일유전자 유전변이의 예측방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2053407

Country of ref document: EP